

# Information Request Email, June 27, 2012 - Octaplas

**From:** Rana, Pratibha  
**Sent:** Wednesday, June 27, 2012 4:40 PM  
**To:** Ammons, Stanley  
**Cc:** Rangetiner, Barbara  
**Subject:** STN 125416/0 Information Request ( 6-27-2012)  
 Our Reference: STN 125416/0  
 Octapharma USA, Inc.

Attention: Stanley Ammons

Dear Mr. Ammons:

We are reviewing your December 22, 2011 biologics license application (BLA) for Pooled Plasma, Solvent Detergent Treated (Human). We are providing the following comments and request for additional information to continue our review:

1. Upon further review and in consideration of the intended use of OctaplasLG<sup>®</sup> as an alternative to FFP for all its clinical indications, FDA requests that Octapharma revise the final product release specification as indicated in the following table.

Parameter	Rationale for Revision	Recommended Limit	Conformance Lot Range
Protein S	----- (b)(4) ----- -----	---(b)(4)---	----- (b)(4) ----- --
$\alpha_2$ -antiplasmin (A2PI)	----- (b)(4) ----- -----	---(b)(4)---	----- (b)(4) ----- -----
Factor V	----- (b)(4) -----	---(b)(4)---	----- (b)(4) -----
Factor XI	----- (b)(4) -----	---(b)(4)---	----- (b)(4) -----
Fibrinogen	----- (b)(4) -----	---(b)(4)---	----- (b)(4) -----
Factor II (Prothrombin)	----- (b)(4) ----- -----	---(b)(4)---	----- (b)(4) ----- -----
Factor X	----- (b)(4) ----- -----	---(b)(4)---	----- (b)(4) ----- -----
Factor VII	----- (b)(4) ----- -----	---(b)(4)---	----- (b)(4) -----
ADAMTS13	----- (b)(4) -----	---(b)(4)---	----- (b)(4) -----

2. Regarding -----(b)(4)----- report titled, "\_\_\_\_(b)(4)-----  
----- (b)(4)-----, Safety, Leachables and Extractables:

- although the report presented some data on extractables and potential leachables, there was no explanation of the data as they related to potential toxicity if leached into the product
- line listings in appendix 1 are illegible

Please provide a meaningful discussion of the safety of the -----(b)(4)--- -----(b)(4)-  
-----

Please submit your response to this information request as an amendment to this file by July 18, 2012 referencing the date of this request.

The action due date for this file is October 22, 2012.

If you have any questions, please contact me.

Sincerely,  
Pratibha Rana  
Pratibha Rana, M.S.  
Regulatory Project Manager

FDA/CBER/OBRR  
Division of Blood Applications  
1401 Rockville Pike  
Rockville, MD 20852  
Office: (301) 827-6124  
Fax: (301) 827-2857  
email: pratibha.rana@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."